BioSpace News Archive

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on competitive intelligence solution.

SGI-DNA announces the launch of Gibson Assembly® RapidAMP™ technology—a novel approach that allows for cell-free synthesis and amplification of transfection-ready quantities of synthetic DNA.

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (NYSE:PFE) for AKCEA-ANGPTL3-LRx following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).

Penumbra, Inc. (NYSE: PEN) today announced that it will host an Investor Day on Tuesday, December 3, 2019 in Boston, MA at 8:30am Eastern Time.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced improved financial and operating results for the third quarter ended September 30, 2019 and provided a corporate strategic update.

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced they will host an Investor and Analyst meeting at the Annual ASHP Midyear Meeting on December 10, 2019.

CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of 4,250,000 common shares.

Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019.

Cerebras Systems, a company dedicated to accelerating Artificial Intelligence (AI) compute, today unveiled its CS-1 system, the world’s fastest AI computer. With every component optimized for AI work, the CS-1 delivers more compute performance at less space and less power than any other system.

BioVentrix, Inc. announced that the U.S. Food and Drug Administration has granted the company Breakthrough Device Designation status for its Revivent TC™ Transcatheter Ventricular Enhancement System for heart failure.